Document Detail

Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control.
Jump to Full Text
MedLine Citation:
PMID:  25371655     Owner:  NLM     Status:  PubMed-not-MEDLINE    
BACKGROUND: Numerous epidemiology studies on dyslipidemia have been conducted in China. However, a nationally representative estimate for dyslipidemia prevalence is lacking. The aim of this study is to appraise the nationwide prevalence, awareness, treatment, and control rates of dyslipidemia in adults in China.
METHODS: We performed a systematic review of the related observational studies published since 2003 by searching English and Chinese literature databases. Meta-analyses were conducted in eligible studies using a random effect model to summarize the dyslipidemia prevalence, awareness, treatment, and control rates. Heterogeneity and publication bias were analyzed. Sensitivity analyses were performed to explain heterogeneity and examine the impact of study quality on the results of meta-analyses.
RESULTS: Thirty-eight papers were included for meta-analyses, with a total sample size of 387,825. The prevalence, awareness, treatment, and control rates of dyslipidemia were 41.9% (95% CI: 37.7% - 46.2%), 24.4% (95% CI: 14.4% - 38.4%), 8.8% (95% CI: 7.7% - 10.0%), and 4.3% (95% CI: 4.1% - 4.5%), respectively. The prevalence of hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, low levels of high-density lipoprotein cholesterol, and high levels of low-density lipoprotein cholesterol were 10.1% (95% CI: 5.8% - 16.9%), 17.7% (95% CI: 14.0% - 22.1%), 5.1% (95% CI: 3.1% - 8.2%), 11.0% (95% CI: 8.0% - 15.0%), and 8.8% (95% CI: 4.1% - 17.8%), respectively. Sensitivity analyses revealed that males had a higher prevalence of dyslipidemia (43.2%) than females (35.6%). Study samples of age 30 and above in the eastern region tended to have higher prevalence of dyslipidemia. The quality of the studies has a slight impact on the pooled estimates.
CONCLUSIONS: The overall pooled prevalence of dyslipidemia in Chinese adults was estimated to be 41.9%, with males having a higher rate than females.
Yuanxiu Huang; Lin Gao; Xiaoping Xie; Seng Chuen Tan
Related Documents :
25263545 - Examining substance use and affective processes as multivariate risk factors associated...
10848725 - Antihypertensive drugs and the risk of idiopathic aplastic anaemia.
18347535 - Minimizing morbidity of organ donation: analysis of factors for perioperative complicat...
17176795 - 3-year impact of a provincial choking prevention program.
25028645 - Serum hdl-c level of iranian adults: results from sixth national surveillance of risk f...
17237135 - Incidence of fatal myocarditis: a population-based study in finland.
Publication Detail:
Type:  Journal Article     Date:  2014-10-28
Journal Detail:
Title:  Population health metrics     Volume:  12     ISSN:  1478-7954     ISO Abbreviation:  Popul Health Metr     Publication Date:  2014  
Date Detail:
Created Date:  2014-11-05     Completed Date:  2014-11-05     Revised Date:  2014-11-07    
Medline Journal Info:
Nlm Unique ID:  101178411     Medline TA:  Popul Health Metr     Country:  England    
Other Details:
Languages:  eng     Pagination:  28     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Popul Health Metr
Journal ID (iso-abbrev): Popul Health Metr
ISSN: 1478-7954
Publisher: BioMed Central, London
Article Information
Download PDF
© Huang et al.; licensee BioMed Central Ltd. 2014
Received Day: 12 Month: 3 Year: 2014
Accepted Day: 1 Month: 10 Year: 2014
Electronic publication date: Day: 28 Month: 10 Year: 2014
pmc-release publication date: Day: 28 Month: 10 Year: 2014
collection publication date: Year: 2014
Volume: 12 Issue: 1
E-location ID: 28
PubMed Id: 25371655
ID: 4219092
Publisher Id: 28
DOI: 10.1186/s12963-014-0028-7

Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control
Yuanxiu HuangAff1 Address:
Lin GaoAff1 Address:
Xiaoping XieAff2 Address:
Seng Chuen TanAff3 Address:
School of Public Health, Central South University, Changsha, China
Outcomes Research, Pfizer Investment Co. Ltd, Beijing, China
Health Economics & Outcomes Research, IMS Health Asia Pacific, 8 Cross Street, #21-01/02/03 PWC Building, Singapore, 048424 Singapore


Dyslipidemia represents one of the major risk factors for atherosclerosis affecting arteries of large and medium size and consequently causing ischemia in the brain, heart, or legs. Coronary artery disease and cerebral stroke represent the major causes of morbidity and mortality among elderly and middle aged subjects [1]. The prevalence of dyslipidemia has increased dramatically in Chinese cities with lifestyle changes over the past decade, and cardiovascular diseases have emerged as a leading cause of death in Chinese adults [2].

Surveys investigating the epidemiological data of dyslipidemia in Chinese adults have been published, but the results vary due to diverse populations of different regions and the use of different diagnosis criteria [2]. An overall appraisal of dyslipidemia epidemiology nationwide in China would potentially benefit future research and policy discussions. We therefore performed meta-analyses by a comprehensive systematic review of all available evidence to synthesize the current dyslipidemia prevalence, awareness, treatment, and control among Chinese adults.

Search strategy and eligibility criteria

Based on the MOOSE guideline [3], we identified epidemiological studies on dyslipidemia in Chinese adults published in English or Chinese between January 2003 and August 2013. The search strategy comprised of a search of Western electronic databases (including Medline, Embase, and CINAHL) and a search of Chinese databases (including SinoMed, CNKI, and Wanfang Data). We used the search terms “dyslipidemia”, “hyperlipidemia”, “epidemiology”, “incidence”, “prevalence”, “awareness rate”, “treatment rate”, “control rate”, “China or Chinese”, and these terms’ variants and combinations.

Eligible studies had to have reported any of the following epidemiological data related to dyslipidemia in sampled populations of Chinese subjects: prevalence, awareness rate, treatment rate, and control rate. The diagnosis criteria was based on the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults [2], which defined dyslipidemia as any one of the following four conditions: hypercholesterolemia (total cholesterol (TC) ≥ 6.22 mmol/L); hypertriglyceridemia (triglycerides (TG) ≥2.26 mmol/L); low levels of high-density lipoprotein cholesterol (HDL-C < 1.04 mmol/L); high levels of low-density lipoprotein cholesterol (LDL-C ≥ 4.14 mmol/L).

Dyslipidemia awareness was defined as a self-report of any prior laboratory diagnosis of dyslipidemia. Treatment was defined broadly as interventions including medication, diet, exercise, and monitoring to manage dyslipidemia. Participants were considered to have controlled dyslipidemia if their serum TC, TG, LDL-C, and HDL-C were within the normal ranges as defined above based on the 2007 Chinese guidelines.

We also applied the following exclusion criteria in filtering the identified publications:

  • Non-human studies
  • Non-research based publications such as press releases, newsletters, forum discussions, etc.
  • Non-epidemiological studies such as basic science research on dyslipidemia.
  • Studies that did not disclose when the data was collected, sample size, or denominator for each reported prevalence or rate.
  • Studies that investigated specific populations such as military, prisoners, specific ethnic groups, etc.
  • Studies that did not apply the diagnosis criteria published in the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.

Study identification and data extraction

We identified relevant studies by searching electronic databases, scanning reference lists, and consulting clinical experts in dyslipidemia. Additionally, studies presented at key conference proceedings were identified. Two reviewers independently examined all the titles and abstracts of the studies retrieved from the searches for potentially eligible studies, then the full text of all potentially relevant citations were obtained and independently assessed by the reviewers to confirm whether they met the inclusion criteria. The results were checked and discussed by the two reviewers to agree upon a final list of included studies.

Using a standardized and predesigned data collection form, all relevant data in each included paper were extracted by two reviewers independently. The data extracted were cross-checked and any unresolved discrepancies were referred to a third reviewer. Where necessary, inputs of a clinical expert advisor were solicited to facilitate discussions among the reviewers.

For each included study, we extracted general information (including authors, year, title, type of publication, etc.), study characteristics (including study design, population, location, diagnosis criteria, sample size, etc.), participants’ characteristics (including age, sex, type of dyslipidemia, etc.). We further recorded the numbers of people with any one type of dyslipidemia condition and reported awareness, treatment, and control rates. The data stratified by sex and dyslipidemia types, where available, were also extracted.

To inform the appropriateness of included studies in the meta-analysis and later evaluate the strength of the evidence, the two reviewers independently assessed and agreed on the quality of each included study using the quality assessment checklist for epidemiological studies [4]. The checklist assesses the quality of studies on a scale of 0 (the worst) to 18 (the best) using predefined criteria on both internal and external validities [4].

Statistical analyses and heterogeneity test

Pooled estimates of the dyslipidemia prevalence, awareness rate, treatment rate, and control rate and their corresponding 95% confidence intervals (CI) were calculated based on the random effect model [5] and stratified by sex and age group (over 18 or over 30 years) where applicable. Heterogeneity between studies was evaluated with the Cochran’s Q test and I2 statistic, which describes the percentage of variation across studies (values of 25%, 50%, and 75% indicate low, moderate, and high degrees of heterogeneity, respectively) [6,7]. Subgroup analyses were performed to investigate potential sources of heterogeneity from different geographical regions and types of dyslipidemia. Publication bias was evaluated by using the funnel plots method. Furthermore, sensitivity analyses were performed to evaluate the influence of particular study on a pooled estimate, which was recalculated by omitting a study each time. Independent or paired t-tests were used as appropriate, and a significant difference was reported if the p-value was less than 0.05. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc, Chicago, USA) and Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood, USA).

Characteristics of included studies

Our searches retrieved 7669 citations. Of these, 6800 were excluded after reading the abstracts, and 831 were further excluded after assessing the full papers, leaving 38 eligible papers for inclusion in our review and analyses (Figure 1) [8-45], which involved a total of 387,825 Chinese people.

Among the 38 included papers, 36 were written in Chinese and two were written in English; 33 studies were cross-sectional surveys and five studies employed census surveys or other designs; 18 studies were conducted in eastern China, 10 studies were conducted in central China, eight studies were conducted in western China, and two surveys crossed regions nationwide (Table 1) [8-45].

Study quality was assessed for the 38 included papers. Four papers had quality scores between eight and 10 points, 13 papers had scores between 11 and 13 points, and 21 papers had scores between 14 and 16 points. Overall study quality was upper-middle and high, and the study quality did not differ significantly among the included studies.

Prevalence of dyslipidemia

Twenty-eight papers reported the total numbers of participants in the studies and those who were diagnosed with dyslipidemia (Figure 2). The pooled prevalence of dyslipidemia in Chinese adults was 41.9% (95% CI: 37.7% – 46.2%). The t-tests showed there were no statistically significant differences between subgroups stratified by age and geographic region (Tables 2 and 3); however, the pooled prevalence of dyslipidemia in males (43.2%) was higher than in female (35.6%) with statistical significance (t = 3.08, p < 0.05).

In terms of the different types of dyslipidemia, the pooled prevalence estimates of hypercholesterolemia (TC), hypertriglyceridemia (TG), mixed hyperlipidemia (TC + TG), low levels of high-density lipoprotein cholesterol (HDL-C), and high levels of low-density lipoprotein cholesterol (LDL-C) are 10.1% (95% CI: 5.8% – 16.9%), 17.7% (95% CI: 14.0% – 22.1%), 5.1% (95% CI: 3.1% – 8.2%), 11.0% (95% CI: 8.0% – 15.0%), and 8.8% (95% CI: 54.1% – 17.8%), respectively. There were no significant differences between age groups within each type of dyslipidemia condition (Table 4 and Additional file 1).

Dyslipidemia awareness, treatment, and control

Using the dyslipidemia awareness rates reported in four studies, we arrived at a pooled estimate of 24.4% (95% CI: 14.4% – 38.4%). Based on the reported dyslipidemia treatment rates in two studies, we estimated a pooled treatment rate of 8.8% (95% CI: 7.7% – 10.0%). There were no significant differences between males and females in terms of dyslipidemia awareness and treatment rates (Table 5). Only one paper reported a dyslipidemia control rate, which was 4.3% (3.1% for males and 5.5% for females).

Sensitivity analysis, publication bias and heterogeneity

Two studies were assessed with a quality score of eight, the lowest among the included studies. In the sensitivity analysis, omitting these two studies resulted in a slight change in the pooled dyslipidemia prevalence estimate, 41.7% from 41.9%. The pooled prevalence of TC, TG, HDL-C, and LDL-C changed to 9.4%, 17.0%, 10.7%, and 8.3% from 10.1%, 17.7%, 11.0%, and 8.8%, respectively. Funnel plots were produced for the prevalence of each type of dyslipidemia (see the Additional file 1). Asymmetric funnels suggest the possibility of publication bias. A moderate degree of heterogeneity was observed in the pooled dyslipidemia prevalence (I2 = 49.9%, Q = 1.00, P < 0.001), awareness rate (I2 = 49.9%, Q = 0.99, P < 0.001), and treatment rate (I2 = 38.0%, Q = 0.721, P = 0.098).


Our systematic review included 38 observational studies conducted in the past decade, covering most of the regions in China, and involving a total of 387,825 participants, representing the adult Chinese population. The pooled estimates from the meta-analyses showed high prevalence of dyslipidemia and low awareness, treatment, and control rates. The study and results are timely, as currently there is a lack of published up-to-date nationwide epidemiological data of dyslipidemia to support the evidence-based approach and management of dyslipidemia in China.

The pooled estimate of dyslipidemia prevalence among Chinese adults is 41.9%, which has more than doubled in the last 10 years [46], approaching the reported prevalence of 53% from the US National Health and Nutrition Examination Survey 2003–2006 [47]. The observed increase of dyslipidemia prevalence in China could possibly be attributed to the increasingly aging population and dramatic lifestyle changes coupled with economic growth, especially changes in cigarette smoking, dietary, and alcohol drinking behaviors among the general population [48].

The study discovered that hypertriglyceridemia (TG) was the most prevalent form of dyslipidemia, with a pooled estimate of 17.7%, followed by low levels of blood high-density lipoprotein cholesterol (HDL-C) (11.0%), hypercholesterolemia (TC) (10.1%), high levels of low-density lipoprotein cholesterol (LDL-C) (8.8%), and mixed hyperlipidemia (TC + TG) (5.1%). As dyslipidemia is one of the well-established risk factors for cardiovascular diseases [47], these results highlight the extensive need for appropriate interventions, both clinical and non-clinical, to treat all types of dyslipidemia. In addition, other considerations such as improving general awareness about dyslipidemia among both patients and health care professionals and promoting healthy diet and lifestyles are equally important in designing and implementing relevant public health strategies.

We calculated and compared the pooled estimates of dyslipidemia prevalence in age groups over 18 years and over 30 years. No significant difference was found between these age groups across different types of dyslipidemia conditions. However, trends of higher prevalence of TC, TG, and LDL-C abnormalities were observed in studies of older participants (≥30 years old) compared to those studies that enrolled younger participants (≥18 years old). We observed the highest estimate at 49.3% (95% CI: 39.4-59.3) among all of the pooled prevalence estimates in people over 30 years old in the eastern region of China. Another study in China concluded that greater burden of diet-related chronic conditions including dyslipidemia has been observed in economically vibrant and highly urbanized areas [49], which are predominantly in the eastern coastal region. More economically developed areas tend to have better access to health care facilities, which might have contributed to diagnosis and hence higher reported prevalence rates in these studies among populations in the eastern region of China.

The systematic review showed that dyslipidemia is more common in men than in women, which is consistent with the findings from American population-based studies [50,51]. There were no significant differences in awareness, treatment, and control rates between the groups of men and women in China. However, studies conducted in the US showed that dyslipidemia was treated and controlled less often in men than in women [50]. A possible explanation for the higher dyslipidemia prevalence observed in men could be their higher probability of cigarette smoking, alcohol, and consumption of foods high in cholesterol.

The quality of studies included in our systematic review were generally good, thus the sensitivity analysis did not demonstrate much difference in the results of meta-analyses when the studies with the lowest quality scores were removed in the analyses. We believe our searches were comprehensive, although the asymmetric funnel plots suggested the possibility of publication bias. The moderate heterogeneity observed could come from the different study settings and populations. We investigated possible sources and performed subgroup analyses, but that still inadequately explained the heterogeneity findings in this study. The recent research of heterogeneity suggested that I2 estimates need to be interpreted with caution when a meta-analysis only includes a limited number of events or trials, in particular when the number of studies for further subgroup analyses is small [52]. Nevertheless, these uncertainties indicate the need of a higher-quality national survey with larger samples with better represented coverage across China.

Our study has some limitations. First, all the included studies were published after 2007 as we used the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults, published in 2007, as the diagnosis criteria [2]. Studies published before 2007 were based on a different set of diagnosis criteria, and therefore have not been included in our meta-analyses. Secondly, we could not investigate the differences in dyslipidemia prevalence between rural and urban areas due to the limited information reported in the included studies. Furthermore, we would like to highlight that the meta-analysis results on awareness, treatment, and control rate need to be interpreted with caution, as the number of studies reporting the relevant data are relatively small.


The pooled estimate of dyslipidemia prevalence among Chinese adults was 41.9%, and hypertriglyceridemia (TG) is the most prevalent dislipidemia condition. The prevalence of dyslipidemia in males was higher than in females. Our study also showed low dyslipidemia awareness, treatment, and control rates in China.


Competing interests

X. Xie is currently employed as a researcher in health outcomes by Pfizer Investment Co. Ltd., at Beijing. The other authors declare that they have no competing interests.

Authors’ contributions

YH, LG, and XX developed the study objective and scope, search strategy, and conducted the literature search, selection of included studies, and endpoints. YH and LG completed data extraction and statistical analyses. XX and SCT reviewed the analyses and contributed to the discussion of the study. The manuscript was drafted, reviewed, and agreed by all co-authors. All authors approved the final version of the manuscript.


This study has been funded by Pfizer Investment Co. Ltd., Beijing, China, including all costs associated with the development and the publishing of the present manuscript. Funding was not contingent upon publication of the manuscript.

1.. Pisciotta L, Bertolini S, Pende A: Lipoproteins, stroke and statins.Curr Vasc Pharmacol 2013, [Epub ahead of print].
2.. Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in AdultsChinese guidelines on prevention and treatment of dyslipidemia in adultsZhonghua Xin Xue Guan Bing Za ZhiYear: 200735539041917711682
3.. Stroup DF,Berlin JA,Morton SC,Olkin I,Williamson GD,Rennie D,Moher D,Becker BJ,Sipe TA,Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) groupJAMAYear: 2000283152008201210.1001/jama.283.15.200810789670
4.. Prins J,Blanker MH,Bohnen AM,Thomas S,Bosch JL. Prevalence of erectile dysfunction: a systematic review of population-based studiesInt J Impot ResYear: 200214642243210.1038/sj.ijir.390090512494273
5.. Schmidt FL,Oh IS,Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in resultsBr J Math Stat PsycholYear: 200962Pt 19712810.1348/000711007X25532718001516
6.. Huedo-Medina TB,Sanchez-Meca J,Marin-Martinez F,Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol MethodsYear: 200611219320610.1037/1082-989X.11.2.19316784338
7.. Higgins JP,Thompson SG,Deeks JJ,Altman DG. Measuring inconsistency in meta-analysesBMJYear: 2003327741455756010.1136/bmj.327.7414.55712958120
8.. Chen YY,Zhu LP,Li A. Epidemiologic characteristics of dyslipidemia in Jiangxi province adultsPract Prev MedYear: 201320234236
9.. Fu YY,Yu JM,Wang JH. Awareness factors analysis of abonormal blood lipid in Beijing communitiesChin J Pract Intern MedYear: 201013840
10.. Fu YY,Yu JM,Wang JH. Current status of dyslipidemia among overweight and obese population in Beijing communityChin J CardiolYear: 201028562566
11.. Gao B,Chen F,Zhang YP. Cross-sectional survey of lipid level in adults orth of nof Qinlin in ShanxiChin J ArteriosclerYear: 201010824827
12.. Gao Y,Liu YB,Li ZM. Relationships between lipid level and fat distribution in Jilin rural area middle-aged populationChin J GerontolYear: 20133321072109
13.. Guan ZJ,Xia CY. The study of prevention and treatment on the incidence of dyslipidemia of rural population in medical examination in BeijingChin Foreign Med ResYear: 2012106365
14.. Guo MH,Han XY,Li Z. The survey about prevalent charateristics of common chronic diseases among adults in Beijing Chaoyang districtChin J Prev Control Chronic DisYear: 201321294296
15.. Hu XL,Xie HB,Xu WH. Dyslipidemia and associated risk factors among residents in the Baimashan Ecological Area of SuichangPrev Treat Cardi -Cereb Vasc DisYear: 201212201203
16.. Hu XZ,Wang ST,Liu ZS. Correlation of dyslipidemia distribution and chronic kidney disease in Zhengzhou older populationChin J GerontolYear: 20113135843586
17.. Jin LZ,Huang RH,Wu WM. Investigation on status of lipid disorders and chronic noninfectious diseases aggregation in Doumen Rural area of Zhuhai cityJ Sun Yat Sen Univ (Med Sci)Year: 200930151154
18.. Li J. Hypertension on Middle-Elderly City Community Residents in Taishan District of Tai’an CityYear: 2010Tai’an, ChinaTaishan Medical University
19.. Li J,Zhang YJ,Sun YH. Investigation of chronic disease incidence in Beijing Sunhe area residentsChin J Gen PractYear: 20119600601
20.. Li JH,Wang LM,Li YC,Bi YF,Jiang Y,Mi SQ,Dai M,Xu Y,Ning G,Zhao WH. Epidemiologic characteristics of dyslipidemia in Chinese adults 2010Zhonghua Yu Fang Yi Xue Za ZhiYear: 201246541441822883727
21.. Li JH,Wang LM,Mi SQ,Zhang M,Li YC,Jiang Y,Xu Y,Dai M,Wang LH. Awareness rate, treatment rate and control rate of dyslipidemia in Chinese adults, 2010Zhonghua Yu Fang Yi Xue Za ZhiYear: 201246868769123157860
22.. Li SL,Yu JX,Zhang YL. Epidemiology of dyslipidemia in residents of Yan’an districtS China J Prev MedYear: 2011371720
23.. Li XH,Li L,Qiao Y. Epidemiologic analysis of dyslipidemia in adult Tibetan population in TibetChin Circ JYear: 200924458460
24.. Li Y,Li WS,Qu WH. Investigation of prevalence rate of dyslipidemia among immigrant population of rural residents in three gorges reservoir areaChin Med HeraldYear: 20129108112
25.. Li Y,Zhai L,Wang HB. The status quo of common chronic diseases among adults in Beijing Haidian districtChin J Prev Control Chronic DisYear: 201018261264
26.. Liang YQ,Zhou YY,Wu YQ. Epidemiologic survey of dyslipidemia among residents aged ≥ 60 years in Rong-Gui community and relationship between dyslipidemia and inter-arm blood pressure differenceNew MedYear: 2013297100
27.. Liao XY,Xu GF,Wu J. Epidemiological study of hyperlipidemia with cardiovascular risk factors in urban and rural communitiesWest China Med JYear: 201311417
28.. Liu DW,Wan J,Liu ZS,Wang P,Cheng GY,Shi XZ. Association between dyslipidemia and chronic kidney disease: a cross-sectional study in the middle-aged and elderly Chinese populationChin Med J (Engl)Year: 201312671207121223557545
29.. Liu XY,Liu L,Zhao Y. Investigation of dyslipidemia prevalence and risk factors in Yinchuan city adultsJ Ningxia Med UnivYear: 2011332731
30.. Luo R,Wang YH,Wang XL. Distribution of dyslipidemia among adult residents in ChongqingJ Chongqing Med UnivYear: 201025710861088
31.. Luo WP,Liu LX,Ma JP. The analysis about residents chronic disease and risk factors of behavior in Xinjiang monitoring stations in 2010Bull Dis Control Prev (China)Year: 2013282023
32.. Mo JF,Song XL,Xu YJ. The correlation research of dyslipidemia prevalence and risk factors about in Guangdong province adultsS China J Prev MedYear: 2013391117
33.. Pang QY,Han B,You A. The Effect Evaluation and Research about Body Mass Index, Waist Circumference and Girth Ratio Predict DyslipidemiaYear: 2008Changzhi, China1st Jinjiluyu Epidemilogy Symposium
34.. Pang QY,Yu DH,Lu J. Distribution characteristics of dyslipedemia and related-risk factors in Henan rural residentsJ Zhengzhou Univ (Med Sci)Year: 200944547550
35.. Shao YQ. Epidemiological study on lipid level and its abnormal rate of Wenzhou community populationMod Pract MedYear: 2011232225
36.. Sheng L,Ye P,Xu RY. Dyslipidemia distribution characteristics of Beijing older male residentsClin FocusYear: 20112615721574
37.. Wang CJ,Li YQ,Li LL,Wang L,Zhao JZ,You AG,Guo YR,Li WJ. Relationship between resting pulse rate and lipid metabolic dysfunctions in Chinese adults living in rural areasPLoS OneYear: 2012711e4934710.1371/journal.pone.004934723145157
38.. Wang JH,Hu DY,Fu YY. Prevalence of dyslipidemia and borderline dyslipidemia and other risk factors of coronary heart disease in residents from Beijing communitiesChin J CardilolYear: 201038175180
39.. Wu ZF,Wang L,Ma GQ. Relationship between body mass index and blood lipid or blood pressure in Tianjin suburbs senile male cohortChin J Prev Control Chronic Non Commun DisYear: 200917293294
40.. Yin L,Li GC,Liu LY. Intervention of main chronic disease and related factors in Hunan province community residentsPract Prev MedYear: 201118611481150
41.. You A. The Prevalence and Influencing Factors of Type 2 Diabetes Mellitus in a Rural Population of Henan ProvinceYear: 2009Zhengzhou, ChinaZhengzhou University
42.. Yuan XH. Investigation of the prevalence of hyperlipidaemia in Yunfu cityChina Mod MedYear: 20129176177
43.. Zhang XW,Ye Z,Zhou D,Zhang J,Wang H,He QF,Fang L,Zhao M,Shu D,Hu R,Gong W. Prevalence of dyslipidemia and its distribution among adults, a cross-sectional study in ZhejiangDis SurveillYear: 2012275395399
44.. Zhao YZ,Feng SG,Li GM. The epidemiological study on dyslipidemia in Nanchong communityMed J West ChinaYear: 20122419481950
45.. Zhou WJ,Zhu Y,Liu P. Epidemiology survey of dyslipidemia among residents in Wuxi City and its influence factorsJiangsu J Prev MedYear: 2012232022
46.. Zhao WH,Zhang J,You Y,Man QQ,Li H,Wang CR,Zhai Y,Li Y,Jin SG,Yang XG. Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in ChinaZhonghua Yu Fang Yi Xue Za ZhiYear: 200539530631016266538
47.. Toth PP,Potter D,Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006J Clin LipidolYear: 20126432533010.1016/j.jacl.2012.05.00222836069
48.. Zhou B,Rao X,Dennis BH,Li Y,Zhuo Q,Folsom AR,Yang J,Li Y,Stamler J,Cao T,Guo C,Thomas RP,Zhao L,Liu X,Tian X,Zheng R,for the PRC-USA Cardiovascular and Cardiopulmonary Research GroupThe relationship between dietary factors and serum lipids in Chinese urban and rural populations of Beijing and Guangzhou. PRC-USA Cardiovascular and Cardiopulmonary Research GroupInt J EpidemiolYear: 199524352853410.1093/ije/24.3.5287672892
49.. Chen CM. Overview of obesity in Mainland ChinaObes RevYear: 20089Suppl 1142110.1111/j.1467-789X.2007.00433.x18307694
50.. Goff DC Jr,Bertoni AG,Kramer H,Bonds D,Blumenthal RS,Tsai MY,Psaty BM. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calciumCirculationYear: 2006113564765610.1161/CIRCULATIONAHA.105.55273716461837
51.. Taylor HA Jr,Akylbekova EL,Garrison RJ,Sarpong D,Joe J,Walker E,Wyatt SB,Steffes MW. Dyslipidemia and the treatment of lipid disorders in African AmericansAm J MedYear: 2009122545446310.1016/j.amjmed.2008.09.04919375555
52.. Thorlund K,Imberger G,Johnston BC,Walsh M,Awad T,Thabane L,Gluud C,Devereaux PJ,Wetterslev J. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analysesPLoS OneYear: 20127e3947110.1371/journal.pone.003947122848355


[Figure ID: Fig1]
Figure 1 

Flow chart of screening and inclusion of studies for review and analysis.

[Figure ID: Fig2]
Figure 2 

Forest plot of 28 studies’ reported prevalence of dyslipidemia.

[TableWrap ID: Tab1] Table 1 

Characteristics of included studies

Author Year Region Age range Number of participants Number of patients diagnosed with dyslipidemia Score of quality assessment
Luo R 2009 Chongqing 18-59 y 20000 6464 12
Guo MH 2011 Beijing 18-79 y 6790 3231 10
Li Y 2008 Beijing 18-79 y 2776 1269 15
Luo WP 2010-2011 Xinjiang ≥ 18 y 2999 2277 14
You AG 2007-2008 Henan ≥ 18 y 20194 - 15
Li JH 2010 National ≥ 18 y 97409 - 15
Mo J 2010 Guangdong ≥ 18 y 3577 2173 16
Pang QY 2006 Henan ≥ 18 y 984 314 9
Pang QY 2007 Henan ≥ 18 y 10127 4392 11
Li JH 2010 National ≥ 18 y 97409 51818 15
Chen YY 2010 Jiangxi ≥ 18 y 3000 1821 14
Zhang XW 2010 Zhejiang ≥ 18 y 17437 8694 14
Li XH 2007-2008 Gansu > 18 y 3038 793 14
Hu XL - Zhejiang > 18 y 2036 - 12
Li SL 2007-2008 Shanxi 20-74 y 1286 459 14
Gao B 2007-2008 Shanxi 20-74 y 3298 1106 15
Jin LZ 2007 Guangdong 20-74 y 1134 - 12
Li J 2009 Beijing 20-78 y 4332 1008 13
Wang JH 2007 Beijing ≥ 20 y 10054 - 13
Fu YY 2007 Beijing ≥ 20 y 10054 3373 16
Yin L 2008-2009 Hunan > 20 y 1544 695 8
Fu YY 2007 Beijing > 20 y 9786 3347 14
Guang ZJ 2011 Beijing 21-91 y 3340 993 14
Liu XY 2008 Ningxia ≥ 25 y 1275 619 14
Yuan XH - Guangdong > 30 y 1053 465 8
Liao XY 2010 Sichuan 35-70 y 2032 474 14
Wang CJ - Henan 35-78 y 16926 7480 14
Shao YQ 2008 Zhejiang > 35 y 7194 - 15
Zhou WJ 2008-2009 Jiangsu > 35 y 2102 922 14
Li J 2009 Shandong > 35 y 1972 - 15
Li Y 2008 Hubei > 35 y 9865 2794 16
Gao Y 2011 Jilin 40-70 y 1332 618 12
Liu DW - Henan ≥ 45 y 4779 - 12
Zhao YZ - Sichuan > 45 y 200 113 11
Wu ZF 2007-2008 Tianjin 50-94 y 1424 - 11
Sheng L 2009 Beijing > 60 y 2685 - 13
Hu XZ 2007 Henan > 60 y 1247 347 13
Liang YQ 2011 Guangdong > 60 y 1135 680 12

[TableWrap ID: Tab2] Table 2 

Prevelance of dyslipidemia by different age groups

Age range Number of studies Total numbers of participants Median (%) Minimum (%) Maximum (%) Pooled prevalence (%) (95% CI)
≥ 18 y 19 203052 43.4 23.3 75.9 42.4 (37.2 ~ 47.7)
≥ 30 y 9 35892 44.2 23.3 59.9 40.9 (33.7 ~ 48.5)
Total 28 238944 44 23.3 75.9 41.9 (37.7 ~ 46.2)

[TableWrap ID: Tab3] Table 3 

Prevalence of dyslipidemia by different regions and sexes

Groups Number of studies Total number of participants Median (%) Minimum (%) Maximum (%) Pooled prevalence (%) (95% CI)
≥ 18 y
Sex Male 15 80145 44.3 25.8 68.9 45.6 (40.0 ~ 51.4)
Female 15 96864 33.7 14.6 56.4 35.9 (29.5 ~ 42.8)
Region Eastern China 8 58092 40 23.3 60.7 40.0 (32.6 ~ 47.9)
Central China 4 15655 44.2 31.9 60.7 45.1 (35.2 ~ 55.5)
Western China 6 31896 34.6 26.1 75.9 41.9 (28.9 ~ 56.1)
≥ 30 y
Sex Male 3 5442 26.2 24.9 45.3 31.5 (20.7 ~ 44.8)
Female 3 7772 30.2 29.9 43 34.1 (26.1 ~ 43.3)
Region Eastern China 3 4290 44.2 43.9 59.9 49.3 (39.4 ~ 59.3)
Central China 4 29370 36.3 27.8 46.4 36.3 (26.6 ~ 47.1)
Western China 2 2232 39.9 23.3 56.5 38.5 (13.1 ~ 72.2)
Sex Male 18 85587 43.7 24.9 68.9 43.2 (37.4 ~ 49.1)
Female 18 104636 32.7 14.6 56.4 35.6 (30.0 ~ 41.7)
Region Eastern China 11 62382 44.2 23.3 60.7 42.5 (36.1 ~ 49.2)
Central China 8 45025 43.8 27.8 60.7 40.6 (33.9 ~ 47.7)
Western China 8 34128 34.6 23.3 75.9 41.0 (30.0 ~ 53.0)

[TableWrap ID: Tab4] Table 4 

Prevelance of dyslipidemia by different dyslipidemia types

Types Age group Number of studies Total number of participants Median (%) Minimum (%) Maximum (%) Pooled prevalence (%) (95% CI)
Hypercholesterolemia (TC) ≥ 18 y 9 143350 7.7 2.5 41.8 7.9 (4.6 ~ 13.2)
≥ 30 y 10 41366 10.8 4.9 48.1 12.5 (5.8 ~ 25.0)
Total 19 184716 8.2 2.5 48.1 10.1 (5.8 ~ 16.9)
Hypertriglyceridemia (TG) ≥ 18 y 9 143350 15.3 4.5 36.9 13.7 (10.7 ~ 17.4)
≥ 30 y 10 41367 18.8 11.7 44.5 22.1 (16.0 ~ 29.7)
Total 19 184717 17.1 4.5 44.5 17.7 (14.0 ~ 22.1)
Mixed hyperlipidemia (TC + TG) ≥ 18 y 3 11249 6.5 1.9 4.2 4.8 (2.4 ~ 9.2)
≥ 30 y 1 2102 - - - -
Total 4 13351 6.4 1.9 8.3 5.1 (3.1 ~ 8.2)
Low blood high-density lipoprotein cholesterol (HDL-C) ≥ 18 y 9 143350 6.9 0.2 57.3 11.0 (6.9 ~ 16.9)
≥ 30 y 9 38129 10.1 1.6 32.8 11.0 (6.6 ~ 17.9)
Total 18 181479 10 0.2 57.3 11.0 (8.0 ~ 15.0)
High blood low-density lipoprotein cholesterol (LDL-C) ≥ 18 y 5 130826 3.1 2.3 67.5 7.6 (2.1 ~ 24.3)
≥ 30 y 7 29843 12.2 1.7 21.3 9.7 (4.5 ~ 19.8)
Total 12 160669 8.8 1.7 67.5 8.8 (4.1 ~ 17.8)

[TableWrap ID: Tab5] Table 5 

Dyslipidemia awareness and treatment rates

Groups Number of studies Total number of participants Median (%) Minimum (%) Maximum (%) Pooled prevalence (%) (95% CI)
Awareness rate
Male 3 28021 25 12.4 25.3 20.1 (11.2 ~ 33.3)
Female 3 28439 31.2 14.7 32.9 25.2 (13.0 ~ 43.1)
Total 4 59807 28.9 13.5 29.8 24.4 (14.4 ~ 38.4)
Treatment rate
Male 2 26620 7.2 6.8 7.6 7.6 (7.3 ~ 7.9)
Female 2 26467 10.9 9.2 12.5 10.6 (7.8 ~ 14.2)
Total 2 53087 9.1 8.4 9.7 8.8 (7.7 ~ 10.0)

Article Categories:
  • Review

Keywords: Keywords Dyslipidemia, Prevalence, Awareness rate, Treatment rate, Control rate, Meta-analysis.

Previous Document:  Hemodynamic impact of isobaric levobupivacaine versus hyperbaric bupivacaine for subarachnoid anesth...
Next Document:  Bone status of children born from mothers with autoimmune diseases treated during pregnancy with pre...